

**SAMPLE — NOT LEGAL ADVICE.** This response letter was generated automatically from publicly available analysis. It has NOT been reviewed by a licensed attorney and SHOULD NOT BE SENT to any party without substantial review and customization by qualified patent counsel. Use as a starting point only.

[Your Name]

[Your Title]

[Your Company]

[Street Address, City, State ZIP]

May 14, 2026

[Opposing Counsel Name]

[Firm Name]

[Address]

**Re: U.S. Patent No. 10980934 — Response to Assertion of Infringement**

Dear Counsel,

We acknowledge receipt of your correspondence asserting infringement of U.S. Patent No. 10980934 (the "10980934 Patent"). After preliminary review, we have substantial concerns about the validity, enforceability, and scope of the asserted claims, summarized below. We reserve all rights and defenses.

## **1. Subject Patent — Summary**

Summary of U.S. Patent 10,980,934

A concise summary of U.S. Patent 10,980,934 is provided below, based on a review of the patent document. As of April 26, 2026, a search of the U.S. Court of Appeals for the Federal Circuit (CAFC) 2026 dockets did not yield any public records of litigation involving this specific patent.

Title: System and method for collecting plasma

Assignee: Haemonetics Corporation

Inventor: Michael Ragusa

Filing Date: July 16, 2020

Issue Date: April 20, 2021

Abstract:

A method for collecting plasma includes determining the weight, height, and hematocrit of a donor, and calculating a donor plasma volume and a target plasma collection volume. The target plasma...

## **2. Validity Concerns under 35 U.S.C. § 102 — Prior Art**

We have identified prior-art references that, in our preliminary view, anticipate one or more asserted claims of the 10980934 Patent:

As a senior US patent analyst, I have reviewed the prior art cited during the prosecution of US Patent 10,980,934 ('934 patent). The following analysis details the most relevant references and their potential to anticipate the patent's claims under 35 U.S.C. § 102.

An anticipation requires that a single prior art reference discloses, either expressly or inherently, each and every element of a claimed invention. The key inventive concepts of the '934 patent revolve around personalizing plasma collection by: 1) calculating a donor's specific plasma volume using height, weight, and hematocrit; 2) setting a target collection volume as a percentage of that total volume; 3) calculating the volume of pure plasma by accounting for anticoagulant; and 4) managing fluid balance to a target intravascular deficit.

#### Analysis of Most Relevant Cited Prior Art

Based on a review of the 38 U.S. patents and applications cited by the examiner, the following references are the most relevant to the core claims of the '934 patent.

---

1. U.S. Patent No. 9,993,588 B2 ("Wegener")

• Full Citation: US...

### **3. Obviousness under 35 U.S.C. § 103**

Independent of § 102, we believe the asserted claims are obvious in view of combinations of prior art that a person having ordinary skill in the art would have been motivated to combine:

Based on an analysis of U.S. Patent 10,980,934 ('934 patent) and the state of the art prior to its priority date of May 30, 2017, several of its claims appear vulnerable to an obviousness challenge under 35 U.S.C. § 103. An obviousness rejection requires that the claimed invention would have been obvious to a person having ordinary skill in the art (PHOSITA) at the time the invention was made.

A PHOSITA in this field would be a biomedical engineer or medical professional with several years of experience in the design and operation of apheresis systems and a thorough understanding of hematology and fluid dynamics as they relate to blood donation.

#### Core Inventive Concepts of the '934 Patent

The central theme of the '934 patent is a move away from generic, weight-based plasma collection limits to a highly individualized and precise methodology. The key steps, as distilled from independent claims 1, 9, and 17, are:

1. Donor-Specific Volume Calculation: Determining a donor's total plasma volume using their specific height, weight, and hematocrit.
2. Personalized Target Volume:...

### **4. Litigation History of the Patent**

Public records reflect that the 10980934 Patent has been the subject of the following litigation, which informs our view of the asserted claims and your client's enforcement posture:

- Haemonetics Corporation v. Terumo BCT, Inc. — 1:25-cv-01409 · United States District Court for the District of Colorado · filed 2025-05-05 · Ongoing
- Terumo BCT Inc. v. Haemonetics Corp. — IPR2026-00045 · Patent Trial and Appeal Board (PTAB) · filed 2025-10-24 · terminated

## 5. Request

In light of the foregoing, we request that your client (i) provide a detailed claim chart identifying each accused product or service and mapping every limitation of each asserted claim, (ii) identify any prior art known to your client, including any references cited during prosecution or reexamination, and (iii) substantiate the basis for any damages or licensing demand. We are prepared to discuss the matter further once we have received and reviewed the foregoing.

Sincerely,

[Your Name]

**DISCLAIMER. This document is a machine-generated sample. The factual assertions, prior-art citations, and legal arguments above are AI-produced and may contain errors, omissions, or outdated information. Do not transmit this letter, in whole or in part, to any party. This is not legal advice; no attorney-client relationship is created by its existence. Consult a licensed patent attorney before responding to any patent-infringement assertion.**

*Generated May 14, 2026 by [ihatepatentrolls.com](http://ihatepatentrolls.com) — sample only.*